siRNA, miRNA (microRNA), and other oligonucleotides: pre-miRNA, mimic miRNA, antimiR…
Transfection of siRNA and other oligonucleotides
Adherent and suspension cells
|Number of transfections|
1 ml of INTERFERin® is sufficient to perform 500-1000 transfections in 24-well plates.
5°C ± 3°C, stable for 6 months (409-01) to at least one year (other packaging sizes) when stored appropriately
INTERFERin® provides very high silencing efficiency already at 1 nM siRNA and can be used in a wide variety of adherent and suspension cells. Using low concentration of siRNA avoids off-target effects, and its gentle mode of action ensure more robust data and excellent cell viability. Easy to use thanks to its compatibility with serum and antibiotics, INTERFERin® is also perfectly suited for transfection of miRNA and other oligonucleotides like pre-miRNA, mimic miRNA, antimiR….
|Amount of reagent||Reference Number|
|5 x 1 ml||409-50|
Less siRNA, less off-target effects
Several publications show that transfecting low siRNA concentrations avoids off-target effects. Indeed, these unwanted non specific side-effects are observed when transfecting siRNA at high concentrations (1,2). Hence, the reliability of the experimental data can be increased by using as little siRNA as possible. This is why INTERFERin® has been specifically designed to provide high silencing efficiency using low siRNA concentrations.
INTERFERin®-mediated delivery of 1 nM of a specific siRNA shows selective and highly efficient knockdown of gene expression, while a competitor (L2K) needs at least 10 nM siRNA to reach 50% silencing efficiency (Fig. 1).
Fig. 1: INTERFERin® only requires 1 nM siRNA for efficient gene silencing. 3LL cells stably expressing firefly luciferase were transfected with an anti-Luc siRNA using INTERFERin® or competitor L2K according to the manufacturer’s recommendation. Luciferase expression was measured after 48 h using a conventional assay. No inhibition was observed with control siRNA.
Amazingly, 50% silencing is still achieved at 10 pM siRNA (Fig. 2).
Fig. 2: INTERFERin® is highly efficient even at extremely low siRNA concentration. A549-GL3Luc cells were transfected in the presence of serum with decreasing concentrations of an anti-Luc siRNA using INTERFERin®. Luciferase expression was measured after 48 h using a conventional assay. No inhibition was observed with control siRNA.
Transfection of 1 nM siRNA targeting endogenous lamin A/C with INTERFERin® drastically reduces lamin gene expression to barely detectable level (Fig. 3).
Fig. 3: Transfection of 1 nM siRNA with INTERFERin® results in efficient and specific gene silencing. CaSki cells were transfected with 1 nM lamin A/C siRNA using INTERFERin®. After 48 h, lamin A/C silencing efficiency was determined by immunofluorescence microscopy.
1. Birmingham, A. et al., (2006) Nature Methods, Vol.3, No3, 199-204
2. Caffrey, D. et al., (2011) PLoS One. 2011;6(7):e21503. Epub 2011 Jul 5.
Suitable for miRNA transfection
Transfection of microRNA (miRNA) oligonucleotides is increasingly being used to analyze biological effects of specific miRNAs on cell function. INTERFERin® is the reagent of choice for delivering miRNA, miRNA mimics or pre-miRNAs.
INTERFERin® is the latest generation siRNA & miRNA transfection reagent, especially designed for high transfection efficiency in a wide variety of cells, resulting in high gene silencing or stimulation of gene expression. Indeed, some miRNA are also known to induce gene expression by association with the promoter of the gene of interest. For example, INTERFERin®-mediated delivery of miR-373 leads to a 3 fold increase in E-Cadherin expression (Fig. 4).
Fig. 4: Transfection of miR-373 with INTERFERin® enhances E-cadherin expression. PC-3 cells were seeded in a 6-well plate and transfected with miR-373 (25 nM) using 8 µl per well of INTERFERin®. 72h after transfection, E-cadherin mRNA expression level was determined by RT-qPCR. The assay was normalized with the HPRT-1 gene expression.
The cationic components of INTERFERin® require very little oligonucleotide amount, resulting in a gentle transfection process. In addition, the easy and robust protocol ensures reproducible results. Oligonucleotides like miRNA can be transfected with small quantities of INTERFERin® resulting in strong gene silencing or stimulation of gene expression. Whatever the concentration of INTERFERin® used, the effect stays approximately the same making INTERFERin® an economical reagent. For example, the fold change using different volume of INTERFERin® is always between 1.5 and 1.8 (Fig. 5).
Fig. 5: INTERFERin® is already efficient at very low amounts. PC-3 cells were seeded in a 6-well plate and transfected with miR-373 (10 nM) using 4, 6 or 8 µl per well of INTERFERin®. 72h post-transfection, E-cadherin expression was analyzed by Western Blot. The assay was normalized using β-actin expression. The quantification was expressed by taking the control situation as reference.
High transfection efficiency associated with high cell viability makes INTERFERin® the reagent of choice for generating relevant data for scientific publications. Indeed, the number of publications using INTERFERin® for miRNA and miRNA related molecules has been exponentially growing since its launch (Fig. 6).
Fig. 6: INTERFERin® is involved in an increasing number of publication about miRNA transfection.
Over 90 % gene silencing
For many adherent cell lines or primary cells, 1 nM siRNA is sufficient to obtain more than 90 % gene silencing. For suspension cell lines, 80 % silencing can still be reached by INTERFERin® using 5 nM siRNA (Table 1).
Table 1: Successfully transfected cell lines and silencing efficiencies obtained with INTERFERin®.
Specific conditions for various cell lines are available in our Polyplus-transfection Database.
Excellent cell viability
When it comes to cell viability, INTERFERin® outperforms other transfection reagents. 48 h after transfection with 1 nM siRNA, cells transfected with INTERFERin® appear healthy, while toxicity is clearly observed with reagent S (Fig. 7).
Fig. 7: INTERFERin® is extremely gentle on cells, as shown in this comparison of cell morphology 48 h after siRNA transfection using INTERFERin® or competitor reagents. A549-GL3Luc cells were transfected in the presence of serum with 1 nM Luciferase siRNA using INTERFERin® or competitors S or H according to the manufacturer’s protocol.
Easy standard protocol
INTERFERin® is ready to use and the protocol is straightforward. A starting concentration of 1 nM siRNA ensures silencing of most genes in most cell types (Fig. 8).
INTERFERin® is compatible with both serum and antibiotics, hence avoiding any time consuming washes and medium changes; furthermore INTERFERin® can be left on the cells without any adverse effects.
Fig. 8: INTERFERin® Protocol
Take a look at our Expert Tips in Genetic Engineering and Biotechnology News .
Video: siRNA transfection using INTERFERin®
Our INTERFERin® reagent is perfectly suited to perform RNA interference experiments, which correspond to the specific inhibition of gene expression promoted by siRNA. siRNAs are gene specific complementary double-stranded RNA oligonucleotides present in the cytoplasm of plants, worms and mammalian cells, and can be efficiently transfected into cells with INTERFERin®.
Every batch of INTERFERin® is tested in house in a transfection assay on A549-Luc cells, constitutively expressing the Luciferase gene. The silencing efficiency obtained using 1 nM siRNA and INTERFERin® for each batch is indicated on the Certificate of Analysis.
In order to download a product protocol or a certificate of analysis, please create an account on Polyplus-transfection® Portal.
Why would you need to create an account?
In this personal area you will have access to:
- Product Protocols
- Certificates of Analysis
- Exclusive webinars/articles
- And surprise features!
Related blog posts
|Cell Line||in vitro|
|Delivered Molecule||Reagent||Results & Citations|
|Mouse embryonic primary cortical neurons||in vitro||siRNA||INTERFERin|
Wojtowicz, A. K. et al. (2016)
Neurotox Res ,
Dibutyl Phthalate (DBP)-Induced Apoptosis and Neurotoxicity are Mediated via the Aryl Hydrocarbon Receptor (AhR) but not by Estrogen Receptor Alpha (ERalpha), Estrogen Receptor Beta (ERbeta), or Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) in Mouse Cortical Neurons
|Mouse peritoneal macrophages||in vitro||siRNA||INTERFERin|
Liu, Z. et al. (2016)
Mol Immunol 78, 57-64
ASF1a enhances antiviral immune response by associating with CBP to mediate acetylation of H3K56 at the Ifnb promoter
|human medulloblastoma cells||in vitro||siRNA||INTERFERin|
Chen, S. M. et al. (2016)
PLoS One 11, e0161299
Blockade of Inhibitors of Apoptosis Proteins in Combination with Conventional Chemotherapy Leads to Synergistic Antitumor Activity in Medulloblastoma and Cancer Stem-Like Cells
|HEK-293T, Mouse peritoneal macrophages, RAW 264.7||in vitro||DNA, mimic miRNA, mimic miRNA and DNA cotransfection, siRNA, siRNA and DNA cotransfection||INTERFERin, jetPRIME|
Zheng, Z. et al. (2016)
J Immunol 196, 1199-208
Bacterial E3 Ubiquitin Ligase IpaH4.5 of Shigella flexneri Targets TBK1 To Dampen the Host Antibacterial Response
Muller, L. K. et al. (2016)
Mol Pharm ,
Physicochemical and Preclinical Evaluation of Spermine-derived Surfactant Liposomes for in vitro and in vivo siRNA-Delivery to Liver Macrophages
|Human airway smooth muscle cells||in vitro||siRNA||INTERFERin|
Naveed, S. U. et al. (2016)
Am J Respir Crit Care Med ,
MMP-1 Activation Contributes to Airway Smooth Muscle Growth and Asthma Severity
|A549, NCI-H1437, NCI-H1563, NCI-H1792, NCI-H1838, NCI-H2087, NCI-H522, NCI-H838||in vitro||siRNA||INTERFERin|
Zhang, B. et al. (2017)
J Cancer 8, 2088-2096
Characterization of the Role of the Malate Dehydrogenases to Lung Tumor Cell Survival
Wouters, K. et al. (2017)
Diab Vasc Dis Res 14, 516-524
The tumour suppressor CDKN2A/p16(INK4a) regulates adipogenesis and bone marrow-dependent development of perivascular adipose tissue
Tietze, S. et al. (2017)
A Poly(Propyleneimine) Dendrimer-Based Polyplex-System for Single-Chain Antibody-Mediated Targeted Delivery and Cellular Uptake of SiRNA
Alshamsan, A. et al. (2009)
Mol Pharm 6, 121-33
Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine